Suggested remit: To appraise the clinical and cost effectiveness of brensocatib within its marketing authorisation for treating non-cystic fibrosis bronchiectasis in people 12 years and over.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6448
Provisional Schedule
- Committee meeting: 1:
- 14 May 2026
- Expected publication:
- 22 July 2026
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Insmed
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Alpha-1 UK Support Group
- Asthma + Lung UK
- European Lung Foundation
- NARA – The Breathing Charity
- NTM Patient Care UK
- PCD Support UK
- Pulmonary Hypertension Association UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Chartered Physiotherapists in Respiratory Care
- Association of Respiratory Nurse Specialists
- Association for Respiratory Technology and Physiology
- British Geriatrics Society
- British Institute of Radiology
- British Paediatric Respiratory Society
- British Thoracic Society
- National Heart and Lung Institute
- Neonatal and Paediatric Pharmacists Group
- Paediatric Bronchiectasis Network UK
- Primary Care Respiratory Society UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infection
- Antimicrobial Resistance National Action Plan Delivery Board for Human Health
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Chest, Heart and Stroke Scotland
- Defra Antimicrobial Resistance Coordination Group
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- National Strategic Clinical Network for Respiratory Conditions
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Northern Ireland Chest, Heart and Stroke Association
- Scottish Medicines Consortium
- Defra Antimicrobial Resistance Coordination Group
- Welsh Government
- Relevant research groups
- Asthma, Allergy and Inflammation Research Charity
- Breathing Matters
- British Association for Lung Research
- BRONCH-UK
- Cochrane Airways Group
- Genomics England
- LifeArc
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 October 2025 | Invitation to participate |
| 08 July 2025 - 05 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6488 |
| 08 July 2025 | In progress. Scoping commencing |
| 12 December 2024 | Referral |
| 10 June 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 21 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual